Aug. 13 at 2:01 PM
$ONCY : FDA Momentum Keeps Building 🧬
Oncolytics Biotech is entering an important stretch for pelareorep with strong clinical data and growing FDA support.
🔹 3 FDA Fast Track Designations across three cancer programs.
🔹 Colorectal cancer study showed a 33% response rate vs. ~10% historically, more than 3X higher.
🔹 Patients went 16.6 months without cancer worsening vs. 5.7 months, with median survival of 27 months vs. 11.2 months.
🔹 Colorectal cancer alone represents an estimated
$3B–
$5B annual opportunity.
🔹 Pelareorep has been evaluated in 1,300+ patients, with collaborations involving Roche, Pfizer, Incyte and others.
🔹 New U.S. patent protection extends through 2044.
📊 TECHNICAL SETUP:
ONCY defended
$0.77 support and is curling higher. Key levels:
$0.85 →
$0.93 →
$1.08 →
$1.18 →
$1.30.
Communicated Disclaimer: https://stockresearchtoday.com/oncy/
Sector Peers:
$REPL
$GNLX
$CADL
$CGON
